Source: International Business Times
AI agents could accelerate the clinical development of cancer medicine by approximately 10 weeks while reducing direct operating costs by as much as $5. 6 million in late-stage trials. Lou Benoist/AFP via Getty Images Artificial intelligence could dramatically cut the time and cost of cancer clinical trials, potentially saving drug developers millions of dollars and accelerating treatments through one of the most expensive stages of pharmaceutical development.
Aller á la Source
Nouvelles connexes
